What is the most appropriate broad-spectrum oral antibiotic for an adult with acute bacterial upper and lower respiratory infection without drug allergies, hepatic or renal impairment, or recent antibiotic use?

Best Broad-Spectrum Antibiotic for Upper and Lower Respiratory Infections

For confirmed bacterial upper and lower respiratory tract infections in adults, amoxicillin-clavulanate is the preferred broad-spectrum oral antibiotic, with respiratory fluoroquinolones (levofloxacin) as the alternative. 1

Critical First Step: Confirm Bacterial Etiology

Most respiratory infections are viral and do not require antibiotics. Before prescribing any antibiotic:

• Upper respiratory infections (common cold, most pharyngitis, acute bronchitis): Over 90% are viral and antibiotics should be avoided 1
• Acute bronchitis: Antibiotics are NOT recommended even with purulent sputum—green or yellow sputum reflects inflammatory cells, not bacteria 1
• Pharyngitis: Only treat if Group A Streptococcus is confirmed by rapid antigen test or culture 1

When Antibiotics Are Indicated

Acute Bacterial Rhinosinusitis (Upper Respiratory)

Reserve antibiotics for patients meeting ANY of these criteria 1:

• Persistent symptoms >10 days without improvement
• Severe symptoms: fever >39°C + purulent nasal discharge or facial pain for ≥3 consecutive days
• "Double sickening": worsening after initial improvement from typical viral URI

First-line antibiotic: Amoxicillin-clavulanate 1

• IDSA guidelines specifically recommend amoxicillin-clavulanate over plain amoxicillin due to coverage of β-lactamase-producing Haemophilus influenzae and Moraxella catarrhalis 1
• Alternative: Doxycycline or respiratory fluoroquinolone (levofloxacin) 1

Community-Acquired Pneumonia (Lower Respiratory)

First-line options 2, 3:

• Amoxicillin-clavulanate (broad β-lactam coverage)
• Levofloxacin showed the highest p-scores for both clinical response (0.71) and lower mortality (0.85) in network meta-analysis 2
• Consider adding a macrolide (azithromycin) to β-lactam if atypical pathogens suspected 3

Key advantage of levofloxacin: Covers typical bacteria (S. pneumoniae, H. influenzae) AND atypical pathogens (Mycoplasma, Chlamydophila, Legionella) 2

Caution with fluoroquinolones: Reserve for well-defined circumstances; prior fluoroquinolone exposure in recent past precludes empirical use due to resistance risk 4

Resistance Considerations

• Macrolide resistance: Erythromycin MICs >0.5 mg/L predict clinical failure; macrolide resistance prevalence in many countries compromises efficacy for pneumococcal infections 4
• Amoxicillin-clavulanate maintains efficacy: High-dose formulations (2000/125 mg twice daily) eradicate amoxicillin-resistant strains with MICs 4-8 mg/L 4, 5
• Fluoroquinolones retain high activity: Effective against resistant respiratory pathogens when used appropriately 4

Practical Algorithm

For upper respiratory tract infection:

1. Confirm bacterial etiology using clinical criteria above
2. If bacterial sinusitis confirmed → Amoxicillin-clavulanate
3. If penicillin allergy → Doxycycline or respiratory fluoroquinolone

For lower respiratory tract infection (pneumonia):

1. Rule out viral etiology
2. If no recent fluoroquinolone use and no contraindications → Levofloxacin 750 mg daily (best mortality data) 2
3. Alternative: Amoxicillin-clavulanate ± macrolide (if atypical coverage needed) 3
4. Avoid fluoroquinolones if recent exposure or low-risk patient where β-lactam adequate

Common Pitfalls to Avoid

• Do not prescribe antibiotics for acute bronchitis—this is the leading cause of inappropriate antibiotic prescribing in adults 1
• Do not use purulent sputum color as indication for antibiotics 1
• Do not use plain amoxicillin for sinusitis—β-lactamase producers require clavulanate 1
• Do not use macrolides alone for H. influenzae—efflux pumps cause resistance in >98% of strains 4
• Antibiotics cause adverse events in 5-25% of patients, with 1 in 1000 having serious events including C. difficile infection 1